StreetInsider.com News Articles

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'

Fri, 16 Oct 2026 10:51:45 -0400

RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

1. Xencor Inc. (XNCR)

Raymond James added Xencor to its top picks list, replacing Relay Therapeutics. The firm anticipates significant interest in Xencor's dataset at ESMO at the end of October. Raymond James sees near-term upside to shares on a positive readout and clear path to pivotal development for

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

1. Xencor Inc. (XNCR)

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

1. Xencor Inc. (XNCR)

Wells Fargo Assumes Xencor, Inc. (XNCR) at Overweight

Wed, 30 Sep 2026 06:23:33 -0400

Wells Fargo analyst Derek Archila assumes coverage on Xencor, Inc. (NASDAQ: XNCR) with a Overweight rating and a price target of $55.00.

For an analyst ratings summary and ratings history on Xencor, Inc. click here. For more ratings news on Xencor, Inc. click here.

Shares of Xencor, Inc. closed at $25.00 yesterday.

Xencor, Inc. (XNCR) PT Raised to $29 at Truist Securities

Mon, 28 Sep 2026 09:09:43 -0400

(Updated - September 28, 2026 9:09 AM EDT)

Truist Securities analyst Gregory Renza raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $29.00 (from $27.00) while maintaining a Buy rating.

The analyst commented: "We see XmAb819's upcoming ESMO update (Oct.25) as a key near-term re-rating event for XNCR, with initial activity, our KOL work and recent discussion with mgmt supporting a potentially favorable setup. We view maintenance of ~25% ORR with >6-mo mPFS and a manageable CRS profile as sufficient to support ph.III advancement. We assign a 70% probability to our Best/Good scenarios and +11.5% PoS-weighted upside. Our ~$800M XmAb819 peak

Xencor, Inc. (XNCR) PT Raised to $29 at Truist Securities

Mon, 28 Sep 2026 09:09:43 -0400

(Updated - September 28, 2026 9:09 AM EDT)

Truist Securities analyst Gregory Renza raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $29.00 (from $27.00) while maintaining a Buy rating.

Xencor, Inc. (XNCR) PT Raised to $35 at Barclays

Fri, 11 Sep 2026 05:30:12 -0400

Barclays analyst Etzer Darout raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $35.00 (from $27.00) while maintaining a Overweight rating.

Xencor, Inc. (XNCR) PT Raised to $21 at JPMorgan

Thu, 03 Sep 2026 08:32:22 -0400

JPMorgan analyst Brian Cheng raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $21.00 (from $14.00) while maintaining a Neutral rating.

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Wed, 02 Sep 2026 16:01:00 -0400

PASADENA, Calif.--(BUSINESS WIRE)--

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.

A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor’s website located at www.xencor.com. A replay of the event will be available for at least 30 days following the presentation.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Wed, 02 Sep 2026 16:01:00 -0400

PASADENA, Calif.--(BUSINESS WIRE)--

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.